Sex hormones and vascular protection in pulmonary arterial hypertension

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 5, 2010, Pages 471-474

  Christou, Helen A ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; AMBRISENTAN; ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CALCIUM CHANNEL; CARBON MONOXIDE; CYCLIC AMP; CYCLIC GMP; CYCLOOXYGENASE 2; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ESTRIOL; ESTROGEN; HEME OXYGENASE 1; ILOPROST; NITRIC OXIDE; NOTCH3 RECEPTOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROGESTERONE; PROSTACYCLIN; RHO KINASE; SEX HORMONE; SILDENAFIL; SITAXSENTAN; TESTOSTERONE; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

CARBON MONOXIDE BLOOD LEVEL; DISEASE ASSOCIATION; FAMILIAL DISEASE; GENE MUTATION; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPERPLASIA; IDIOPATHIC DISEASE; LUNG VASOCONSTRICTION; MORTALITY; MUSCLE CONTRACTILITY; MUSCLE GROWTH; NONHUMAN; NOTE; PNEUMONIA; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; STEM CELL; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; ESTRADIOL; GONADAL STEROID HORMONES; HUMANS; HYPERTENSION, PULMONARY; PROGESTERONE; PULMONARY ARTERY; TESTOSTERONE;

EID: 78650224863     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181fa8e20     Document Type: Note

References (51)

1. Farber HW. The status of pulmonary arterial hypertension in 2008. Circulation. 2008;117:2966-2968.
2. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest.;137:376-387.
3. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164-172.
4. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(Suppl):78S-92S.
5. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of pulmonary arterial hypertension (PAH) patients in the United States: how the REVEAL Registry differs from historic and non-US contemporary registries. Chest. June 17, 2010. [Epub ahead of print].
6. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049-2056.
7. Adnot S, Raffestin B, Eddahibi S, et al. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest. 1991;87:155-162.
8. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81-84.
9. Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698-702.
10. Michelakis ED, McMurtry MS, Wu XC, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002;105:244-250.
11. Sweeney M, Yuan JX. Hypoxic pulmonary vasoconstriction: role of voltage-gated potassium channels. Respir Res. 2000;1:40-48.
12. Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation. 2007;115:2331-2339.
13. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-2821.
14. Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol. 2004;287:L656-L664.
15. Ivy D, McMurtry IF, Yanagisawa M, et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2001;280:L1040-L1048.
16. Laudi S, Trump S, Schmitz V, et al. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol. 2007;293:L630-L638.
17. Geraci MW, Gao B, Shepherd DC, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999;103:1509-1515.
18. Christou H, Morita T, Hsieh CM, et al. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygen-ase-1 in the rat. Circ Res. 2000;86:1224-1229.
19. Fredenburgh LE, Liang OD, Macias AA, et al. Absence of cyclo-oxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation. 2008;117:2114-2122.
20. Li X, Zhang X, Leathers R, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med. 2009;15:1289-1297.
21. Yet SF, Perrella MA, Layne MD, et al. Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest. 1999;103:R23-R29.
22. Gillespie MN, Olson JW, Reinsel CN, et al. Vascular hyperresponsiveness in perfused lungs from monocrotaline-treated rats. Am J Physiol. 1986;251:H109-H114.
23. Fullerton DA, Hahn AR, McIntyre RC Jr. Mechanistic imbalance of pulmonary vasomotor control in progressive lung injury. Surgery. 1996;119:98-103.
24. Shimoda LA, Sham JS, Sylvester JT. Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol Res. 2000;49:549-560.
25. Mam V, Tanbe AF, Vitali SH, et al. Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia-and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther. 2010;332:455-462.
26. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159-165.
27. Klings ES, Farber HW. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:2521-2522; author reply 2521-2522.
28. Mitani Y, Ueda M, Komatsu R, et al. Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. Eur Respir J. 2001;17:316-320.
29. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80:1198-1206.
30. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54(Suppl):S10-S19.
31. Minamino T, Christou H, Hsieh CM, et al. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA. 2001;98:8798-8803.
32. Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 2006;168:659-669.
33. Frid MG, Li M, Gnanasekharan M, et al. Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1059-1072.
34. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26:858-863.
35. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010; 55:1915-1922.
36. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.
37. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
38. McMurtry MS, Archer SL, Altieri DC, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115:1479-1491.
39. Ito T, Okada T, Miyashita H, et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res. 2007;101:734-741.
40. Baber SR, Deng W, Master RG, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1120-H1128.
41. Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108:1640-1645.
42. Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 2007;49:1566-1571.
43. Daley E, Emson C, Guignabert C, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008;205:361-372.
44. Smith AM, Jones RD, Channer KS. The influence of sex hormones on pulmonary vascular reactivity: possible vasodilator therapies for the treatment of pulmonary hypertension. Curr Vasc Pharmacol. 2006;4:9-15.
45. Patel KM, Lahm T, Crisostomo PR, et al. The effects of endogenous sex hormones and acute hypoxia onvasoconstriction in isolated rat pulmonary artery rings. J Surg Res. 2008;146:121-126.
46. Mueck AO, Seeger H. 2-Methoxyestradiol-biology and mechanism of action. Steroids. 2010;75:625-631.
47. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004;286:R233-R249.
48. Murphy JG, Khalil RA. Gender-specific reduction in contractility and [Ca(2+)](i) in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol. 2000;278:C834-C844.
49. Kanashiro CA, Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol. 2001;280:C34-C45.
50. Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension. 2004;44:796-799.
51. Wingrove CS, Garr E, Godsland IF, et al. 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta. 1998;1406:169-174.